SCHEMBL7004876

SCHEMBL7004876

O=C(O)CCCN(CCCCCCNc1nsc2nccn12)S(=O)(=O)c1cccc2ccccc12

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
F13A1 P00488 10/20 0.56
TGM1 P22735 4/20 0.51
HTR2A P28223 2/20 0.36
HTR2C P28335 2/20 0.36
HTR7 P34969 2/20 0.36
KEAP1 Q14145 1/20 0.36
NFE2L2 Q16236 1/20 0.36
NPY5R Q15761 3/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
GFER P55789 1/20 0.35
KMT2A Q03164 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HSD17B10 Q99714 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
AGTR1 P30556 1/20 0.35
AGTR2 P50052 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7005996 0.93 F13A1 (0.54) F13A1TGM1HTR2AHTR2CHTR7
SCHEMBL7008472 0.92 F13A1 (0.57) F13A1TGM1HTR2AHTR2CHTR7
SCHEMBL7004053 0.89 F13A1 (0.54) F13A1TGM1ALDH1A1KMT2A
SCHEMBL7007196 0.88 F13A1 (0.54) F13A1TGM1HTR2AHTR2CHTR7
SCHEMBL7080074 0.87 F13A1 (0.59) F13A1TGM1HTR2AHTR2CHTR7
SCHEMBL7007271 0.85 F13A1 (0.56) F13A1TGM1HTR2AHTR2CHTR7
SCHEMBL7007005 0.82 F13A1 (0.75) F13A1TGM1HTR2AHTR7NPY5R
SCHEMBL7004258 0.80 F13A1 (0.52) F13A1TGM1
SCHEMBL7007199 0.79 F13A1 (0.62) F13A1TGM1HTR2AHTR7NPY5R
SCHEMBL7002966 0.79 F13A1 (0.52) F13A1TGM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030225007-A1 Sulfonamide derivatives of 3-substituted imidazol[1,2-d]-1,2,4-thiadiazoles and 3-substituted-[1,2,4] thiadiazolo[4,5-a] benzimidazole as inhibitors of fibrin cross-linking and transglutaminases APOTEX INC. 2003-12-04 US disclosed
EP-1348710-A1 Sulfonamide derivatives of 3-substituted imidazo[1,2-D]-1,2,4-thiadiazoles and 3-substituted-[1,2,4]thiadiazolo[4,5-A]benzimidazole as inhibitors of fibrin cross-linking and transglutaminases Apotex Inc. (CA) 2003-10-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225007-A1 Sulfonamide derivatives of 3-substituted imidazol[1,2-d]-1,2,4-thiadiazoles and 3-substituted-[1,2,4] thiadiazolo[4,5-a] benzimidazole as inhibitors of fibrin cross-linking and transglutaminases PIGS, FGB, SERPINE1 F13A1 14/4885TGM1 7/4885HTR2A 2783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.